ClinicalTrials.gg
RecruitingNCT06283927RECSURUpdated Feb 28, 2024

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

An observational study in Glioblastoma, Glioblastoma Multiforme and Glioblastoma, IDH-wildtype, sponsored by Jasper Gerritsen. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Jasper Gerritsen · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
464
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
15th of 79
464 · median 60
Started
2023
with 57 others
Observational
79 of 1,303
20 open now
Primary completion
2027-01
later than 111 of 322 live
Registered
1,179th of 1,303
by date

Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 15th largest by planned enrollment of the 79 observational ones that give a count, is one of 58 that started in 2023, is one of 79 observational ones, reaches primary completion later than 111 of the 322 other live ones, and was the 1,179th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,303 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups.

This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) overall survival. Secondary endpoints are: 1) progression-free survival (PFS), 2) NIHSS deterioration at 3 months and 6 months after surgery, 3) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

The study has been approved by the Medical Ethics Committee (METC Zuid-West Holland/Erasmus Medical Center; MEC-2020-0812). The results will be published in peer-reviewed academic journals and disseminated to patient organisations and media.

Read the detailed description

This is an international, multicenter, prospective, cohort study. Eligible patients are operated or receive best oncological treatment with a 1:1 ratio with a sequential computer-generated random number as subject ID. Intraoperative mapping techniques and/or surgical adjuncts can be used in both treatment arms to ensure the safety of the resection (to minimize the risk of postoperative deficits).

Study patients undergo tumor re-resection or receive best oncological treatment and will undergo evaluation at presentation (baseline) and during the follow-up period at 6 weeks, 3 months, and 6 months postoperatively. Motor function will be evaluated using the NIHSS (National Institute of Health Stroke Scale) and MRC (Medical Research Council) scale. Language function will be evaluated using a standard neurolinguistic test-battery consisting of the Aphasia Bedside Check (ABC), Shortened Token test, Verbal fluency, Picture description and Object naming. This neurolinguistic test-battery is the result of a consensus between the participating centers. Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). Overall patient functioning with be assessed with the Karnofsky Performance Scale (KPS) and the ASA (American Society of Anesthesiologists) physical status classification system for comorbidities. Health-related quality of life (HRQoL) will be assessed with the EQ-5D questionnaire and the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Overall survival and progression-free survival will be assessed. We expect to complete patient inclusion in 4 years. The estimated duration of the study, including follow-up, will be 5 years.

The primary study objective is to evaluate the safety and efficacy of re-resection versus best oncological treatment (neurological morbidity and overall survival) in recurrent glioblastoma patients as expressed by NIHSS scores and survival data. Secondary study objectives are to study the overall progressive-free survival (PFS), long-term neurological morbidity (3 months and 6 months postoperatively), health-related quality of life (HRQoL), and Serious Adverse Events (SAEs) after resection versus best oncological treatment as expressed by progression on follow up MRI scans based on the RANO criteria24 for tumor progression; NIHSS scores, quality of life questionnaires (EORTC QLQ C30, EORTC QLQ BN20, EQ-5D), and registration of SAEs.

Patients will be recruited for the study from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals of the ENCRAM Research Consortium, located in Europe and the United States.

03

Conditions studied

  • Glioblastoma
  • Glioblastoma Multiforme
  • Glioblastoma, IDH-wildtype
  • Glioblastoma Multiforme of Brain
  • Glioblastoma Multiforme, Adult
  • Recurrent Glioblastoma
  • Astrocytoma, Malignant
  • Astrocytoma of Brain

Keywords

  • Glioblastoma
  • Radiotherapy
  • Chemotherapy
  • Re-resection
  • Resection
  • Overall survival
  • Progression-free survival
  • Neurological morbidity
  • Safety
  • Serious Adverse Events
  • Quality of life
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with recurrent glioblastoma will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤90 years
  2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma
  3. The tumor is suitable for resection (according to neurosurgeon)
  4. Written

Exclusion criteria

Exclusion Criteria:

  1. Tumors of the cerebellum, brainstem, or midline
  2. Medical reasons precluding MRI (e.g., pacemaker)
  3. Inability to give written
  4. Secondary high-grade glioma due to malignant transformation from low-grade glioma
  5. Clinical data unavailable for the newly diagnosed setting
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
464 participants (estimated)
Patient registry
No

Groups and cohorts

  • Re-resection

    Resection of the recurrent tumor

    Procedure: Re-resection

  • Best oncological treatment

    Best oncological treatment consisting of re-challenge temozolomide, re-irradiation, experimental therapy, or best supportive care

    Drug: Temozolomide · Drug: Lomustine · Radiation: Re-irradiation · Procedure: Experimental therapy · Other: Best supportive care

Interventions

  • ProcedureRe-resection

    Resection of the recurrent tumor

  • Re-challenge Temozolomide chemotherapy

  • Second line chemotherapy with Lomustine

  • RadiationRe-irradiation

    Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor

  • ProcedureExperimental therapy

    Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)

    Also known as: Immunotherapy, Oncolytic virotherapy

  • OtherBest supportive care

    Best supportive care, focused on alleviating symptoms

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time from diagnosis to death from any cause

    Time frame: Up to 5 years postoperatively

  2. Neurological morbidity at 6 weeks

    NIHSS deterioration of 1 point or more at 6 weeks after surgery

    Time frame: 6 weeks postoperatively

Secondary outcomes

  1. Neurological morbidity at 3 months

    NIHSS deterioration of 1 point or more at 3 months after surgery

    Time frame: 3 months postoperatively

  2. Neurological morbidity at 6 months

    NIHSS deterioration of 1 point or more at 6 months after surgery

    Time frame: 6 months postoperatively

  3. Progression-free survival

    Time from diagnosis to disease progression (occurrence of a new tumor lesions with a volume greater than 0.175 cm3, or an increase in residual tumor volume of more than 25%) or death, whichever comes first

    Time frame: Up to 5 years postoperatively

  4. Residual tumor volume

    Residual tumor volume of the contrast-enhancing and non-contrast enhancing part, as assessed by a neuroradiologist on postoperative MRI scan (T1 with contrast and FLAIR sequences) using manual or semi-automatic volumetric analyses (Brainlab Elements iPlan CMF Segmentation, Brainlab AG, Munich, Germany; or similar software)

    Time frame: Within 72 hours postoperatively

  5. Quality of life at 6 weeks (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 weeks postoperatively

  6. Quality of life at 3 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 3 months postoperatively

  7. Quality of life at 6 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 months postoperatively

  8. Quality of life at 6 weeks (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 weeks postoperatively

  9. Quality of life at 3 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 3 months postoperatively

  10. Quality of life at 6 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 months postoperatively

  11. Quality of life at 6 weeks (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 weeks postoperatively

  12. Quality of life at 3 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 3 months postoperatively

  13. Quality of life at 6 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 months postoperatively

  14. Serious Adverse Events

    Serious Adverse Events within 6 weeks postoperatively

    Time frame: 6 weeks postoperatively

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 48 months is below that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06283927
Lead sponsor
Jasper Gerritsen
Responsible party
Jasper Gerritsen (Dr., Erasmus Medical Center) — Sponsor-investigator
First posted
Feb 28, 2024
Start date
Jan 1, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Feb 28, 2024

Study contacts

Jasper Gerritsen, MD PhD
Contact
j.gerritsen@erasmusmc.nl
31107036130
Arnaud Vincent, MD PhD
Contact
a.vincent@erasmusmc.nl
31107034211
Jasper Gerritsen, MD PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion